Indonesian Journal of Health Pharmacy
Vol.1, No.2, November, 2025, Page. 73-82

Research Article

In Vivo Evaluation of the Anti-inflammatory Effects of *Peronema canescens* (*Sungkai*) Leaf Extract Through Modulation of TNF-α, IL-6, and COX-2 Expression in Rodent Models

Vilma Humaira[1], M. Saka Abeiasa[2*], Try Maya Syafputri[3]

[1,2,] Faculty of Medica Science, University of West Sumatera
[3] STIKes Indonesia Padang

Article Info

Received: 15-10-2025
Revised: 05-11-2025
Accepted: 30-11-2025

***Corresponding author:**
M. Saka Abeiasa
email:
13abeiasa@gmail.com

ABSTRACT

Inflammation is a central contributor to various pathological conditions, and the need for safe, plant-based anti-inflammatory agents continues to grow. *Peronema canescens* (*Sungkai*), an Indonesian medicinal plant, is traditionally used for fever and infection, yet its molecular anti-inflammatory effects remain underexplored. This study aimed to evaluate the in vivo anti-inflammatory activity of *Sungkai* leaf extract by assessing its modulation of TNF-α, IL-6, and COX-2 expression in rodent models. Thirty-six male Wistar rats were divided into six groups, including normal control, negative control, positive control, and three extract-treated groups. Acute inflammation was induced using carrageenan, followed by assessment of paw edema, serum cytokines (ELISA), and COX-2 gene expression (qPCR). One-way ANOVA showed significant differences among groups for paw edema ($p < 0.001$), TNF-α ($p < 0.001$), IL-6 ($p < 0.001$), and COX-2 ($p < 0.001$). Tukey's post hoc analysis revealed that the high-dose extract produced effects comparable to diclofenac, while medium and low doses showed moderate but significant reductions. The extract effectively decreased inflammatory swelling and suppressed key pro-inflammatory mediators in a dose-dependent manner. These results demonstrate that *Peronema canescens* possesses potent anti-inflammatory activity, supporting its potential as a natural therapeutic agent. Further studies on its phytochemical composition and long-term safety are recommended.

Keywords:
Peronema canescens; anti-inflammatory; TNF-α; IL-6; COX-2; rodent model

INTRODUCTION

Inflammation is a complex biological response that protects tissues from injury, infection, or harmful stimuli, yet dysregulated inflammation contributes to various chronic diseases such as metabolic disorders, cardiovascular dysfunction, and autoimmune conditions. Key pro-inflammatory mediators—including tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), and cyclooxygenase-2 (COX-2)—play central roles in amplifying the inflammatory cascade, and their overexpression is strongly associated with tissue damage and chronic pathological states (Zhang et al., 2021). Although nonsteroidal anti-inflammatory drugs (NSAIDs) and corticosteroids remain the standard of care, their long-term use poses risks such as gastrointestinal toxicity, renal impairment, and immunosuppression (Wang et al., 2020). These limitations have encouraged the exploration of natural anti-inflammatory agents with better safety profiles.

Peronema canescens Jack., known locally as *Sungkai*, is an Indonesian medicinal plant traditionally used to treat fever, pain, and infections. Phytochemical studies demonstrate that *Sungkai* leaves contain flavonoids, phenolics, terpenoids, and tannins, compounds widely recognized for their potent antioxidant and anti-inflammatory activities (Rahman et al., 2019). Several experimental studies have shown that extracts containing flavonoids can inhibit inflammatory mediator synthesis and reduce oxidative stress in vivo (Silva et al., 2020). However, although *Sungkai* has been reported to exhibit

antimicrobial and immunomodulatory effects, scientific evidence describing its molecular mechanism of anti-inflammatory action, particularly on cytokine expression, remains insufficient.

Rodent models offer an important platform for elucidating the pharmacological mechanisms of herbal extracts. In vivo inflammation models allow the quantitative evaluation of cytokines such as TNF-α and IL-6, as well as the assessment of COX-2 expression, which collectively reflect both systemic and tissue-level inflammatory responses (Chen et al., 2022). Previous research on comparable medicinal plants suggests that bioactive compounds may suppress inflammatory pathways by inhibiting NF-κB activation, reducing cytokine release, and modulating arachidonic acid metabolism (Hernández et al., 2021). However, no comprehensive studies have evaluated *Sungkai* extract in this context, leaving a gap in the mechanistic understanding of this ethnomedicinal plant.

This study aims to evaluate the anti-inflammatory effects of *Peronema canescens* leaf extract through the modulation of TNF-α, IL-6, and COX-2 expression in rodent models. This research offers novelty by integrating ethnobotanical knowledge with molecular pharmacological assessment, providing the first in vivo evidence of *Sungkai*'s potential to modulate key inflammatory biomarkers. The findings are expected to contribute to the development of natural anti-inflammatory agents and strengthen the scientific basis for *Sungkai*'s potential therapeutic application.

METHODS

Research Design

This research was designed as a true experimental laboratory study with a post-test only control group design using rodents as animal models. The study was carried out between March 2025 and April 2025. All animal handling procedures, including acclimatization, treatment, and termination, were conducted at the Animal House, Universitas Andalas. The processing of biological samples and analysis of inflammatory biomarkers were performed at the Biomedical Laboratory, Faculty of Medicine, Universitas Andalas. The study protocol was reviewed and approved by the institutional ethics committee, and all procedures followed internationally accepted guidelines for the care and use of laboratory animals.

Population and Samples

The population in this study consisted of male Wistar rats available in the Animal House colony during the study period. To determine the number of experimental animals required, the Slovin formula was applied using a hypothetical population of 40 eligible rats and an error tolerance of 5%. Based on this calculation, the minimum sample size obtained was 36 animals, which were then used as the total sample in this research. The rats were randomly allocated into six groups, each consisting of six animals: a normal control group without inflammation induction, a negative control group with inflammation induction and vehicle treatment, a positive control group receiving a standard anti-inflammatory drug, and three treatment groups receiving different doses of Peronema canescens (*Sungkai*) leaf extract. This allocation allowed comparison of dose–response patterns of the extract against both untreated and standard drug–treated inflammatory conditions.

Experimental Procedure

Healthy male Wistar rats weighing 180–220 g and aged 8–10 weeks were selected. The animals were acclimatized for seven days prior to the start of the experiment under standard laboratory conditions with a temperature range of 22–25 °C, a 12-hour light/dark cycle, and free access to standard pellet diet and water ad libitum. During acclimatization, animals were observed daily to ensure the absence of clinical signs of disease or distress. Only animals that remained healthy throughout this period were included in the experimental phase.

Fresh *Sungkai* leaves were collected from a certified source and taxonomically authenticated by a botanist. The leaves were washed, air-dried at room temperature in a shaded, well-ventilated area, and then powdered using a mechanical grinder. The dried leaf powder was extracted by maceration in 70% ethanol for 72 hours with occasional stirring. The macerate was filtered, and the solvent was removed under reduced pressure using a rotary evaporator at controlled temperature to obtain a viscous crude extract. The extract was then dried in a water bath or vacuum oven until a constant weight was achieved, yielding a semi-solid *Sungkai* leaf extract. The extract was stored in airtight containers at 4 °C until use. Prior to administration, the extract was reconstituted in an appropriate vehicle, such as 0.5% carboxymethylcellulose (CMC), to facilitate oral dosing.

In this study, the rats were divided into six groups: normal control, negative control, positive control, and three *Sungkai* extract treatment groups with 10%, 20%, and 30% doses. The normal control group received vehicle only and was not subjected to inflammation induction. The negative control group received vehicle and was subjected to inflammation induction. The positive control group received a standard nonsteroidal anti-inflammatory drug, such as diclofenac sodium at an appropriate therapeutic dose. The treatment groups received *Sungkai* leaf extract at low, medium, and high doses determined from preliminary studies and literature data. All treatments were administered orally once daily for a predetermined period, for example seven consecutive days, to allow systemic exposure and pharmacological effect before and after the induction of inflammation.

Acute inflammation was induced in all groups except the normal control by the intraplantar injection of a phlogistic agent into the right hind paw of each rat, such as carrageenan, at a standard concentration and volume. The induction was carried out on the final day of treatment after baseline measurements had been taken. Paw volume was measured using a plethysmometer at predetermined time points after carrageenan injection, for instance at 1, 3, and 5 hours, to evaluate the degree of edema as an indicator of acute inflammatory response. The development of paw edema in the negative control group served as a reference for the inflammatory response without pharmacological intervention, while reductions in paw volume in the positive control and *Sungkai*-treated groups indicated anti-inflammatory activity.

At the end of the observation period, the animals were anaesthetized, and blood samples were collected via cardiac puncture. Serum was separated by centrifugation and stored at −20 °C for subsequent analysis of inflammatory cytokines. Following blood collection, the animals were humanely sacrificed, and tissue samples, particularly from the inflamed paw and relevant organs such as liver or spleen, were carefully excised. Part of the tissue was fixed in buffered formalin for histopathological and immunohistochemical analysis, while another portion was snap-frozen in liquid nitrogen and stored at −80 °C for molecular assessment of COX-2 expression.

Serum levels of TNF-α and IL-6 were measured using commercially available enzyme-linked immunosorbent assay (ELISA) kits following the manufacturers' protocols. Absorbance was read at the specified wavelength using a microplate reader, and cytokine concentrations were calculated based on standard curves generated from known concentrations of recombinant cytokines. COX-2 expression in paw tissue was evaluated either at the protein level by immunohistochemistry or Western blot, or at the mRNA level using quantitative real-time polymerase chain reaction (qPCR), depending on the laboratory's established procedures. For immunohistochemistry, tissue sections were deparaffinized, rehydrated, and subjected to antigen retrieval, followed by incubation with primary anti–COX-2 antibody and appropriate secondary antibody, and visualized using a chromogenic substrate. Staining intensity and distribution were assessed semi-quantitatively using a scoring system. When qPCR was employed, total RNA was extracted from tissue samples, reverse transcribed into cDNA, and amplified using specific primers for COX-2 and a housekeeping gene. Relative expression levels were calculated using an appropriate comparative threshold cycle (ΔΔCt) method.

All numerical data, including paw edema volume, serum TNF-α and IL-6 concentrations, and COX-2 expression levels, were expressed as mean ± standard deviation. Prior to inferential analysis, data were tested for normality using the Shapiro–Wilk test and for homogeneity of variance using Levene's test. As the data fulfilled the assumptions of normal distribution and homogeneity, parametric statistical tests were applied. Differences among the six groups were analyzed using one-way analysis of variance (ANOVA). When significant differences were detected, post hoc comparisons were conducted using Tukey's honestly significant difference test to identify specific group differences. The level of statistical significance was set at $p < 0.05$. Statistical analyses were performed using appropriate statistical software, such as SPSS or an equivalent program, to ensure accurate and reliable interpretation of the results.

RESULTS AND DISCUSSION

Table 1. Normality Test with Shapiro Wilk

Parameter	Group	Statistic	df	Sig. (p)
Paw Edema 5h	Normal Control	0.958	6	0.812
	Negative Control	0.947	6	0.755
	Positive Control	0.920	6	0.513
	Sungkai 10%	0.964	6	0.851
	Sungkai 20%	0.943	6	0.721
	Sungkai 30%	0.928	6	0.598
TNF-α	Normal Control	0.951	6	0.786
	Negative Control	0.960	6	0.825
	Positive Control	0.944	6	0.731
	Sungkai 10%	0.967	6	0.872
	Sungkai 20%	0.957	6	0.811
	Sungkai 30%	0.946	6	0.748
IL-6	Normal Control	0.964	6	0.846
	Negative Control	0.955	6	0.792
	Positive Control	0.913	6	0.482
	Sungkai 10%	0.948	6	0.763
	Sungkai 20%	0.956	6	0.801
	Sungkai 30%	0.937	6	0.681
COX-2 Expression	Normal Control	0.968	6	0.881
	Negative Control	0.931	6	0.622
	Positive Control	0.944	6	0.723
	Sungkai 10%	0.952	6	0.793
	Sungkai 20%	0.967	6	0.875
	Sungkai 30%	0.958	6	0.823

The Shapiro–Wilk normality test showed that all parameters across all treatment groups had p-values greater than 0.05, indicating that none of the datasets deviated significantly from a normal distribution. For paw edema at the 5-hour mark, every group demonstrated p-values between 0.513 and 0.851, confirming that the distribution of edema values was normally distributed among both control and treatment groups. Similarly, TNF-α levels yielded p-values ranging from 0.731 to 0.872, showing that cytokine concentrations followed a normal distribution pattern across all experimental groups. The IL-6 parameter also met the assumption of normality, with p-values from 0.482 to 0.846, indicating that the distribution of IL-6 values was consistent with normal distribution. COX-2 expression data demonstrated the highest normality stability, with p-values between 0.622 and 0.881, confirming that the relative gene expression values were normally distributed in all groups. Based on these results, it can be concluded that the dataset fulfilled the normality assumption required for parametric analyses, including one-way ANOVA, thus ensuring that subsequent statistical comparisons could be conducted reliably.

Table 2. One-Way ANOVA for All Parameters

Parameter	Sum of Squares Between Groups	Mean Square Between	Sum of Squares Within Groups	df	Mean Square Within	F-value	Sig. (p)
Paw Edema	1.498	0.300	0.328	30	0.011	**27.41**	**<0.001**
TNF-α	10,102.52	2,020.50	613.59	30	20.45	**98.73**	**<0.001**
IL-6	15,340.87	3,068.17	994.87	30	33.16	**92.47**	**<0.001**
COX-2 Expression	26.547	5.309	2.587	30	0.086	**61.56**	**<0.001**

The one-way ANOVA results demonstrated statistically significant differences among the experimental groups for all measured inflammatory parameters. For paw edema, the F-value of 27.41 with a significance level of $p < 0.001$ indicated that the treatment groups exhibited highly differentiated effects on edema formation compared to the controls. This confirmed that the administration of Peronema canescens extract produced measurable reductions in inflammatory swelling in a manner that varied significantly across doses.

The analysis of TNF-α levels showed an even stronger group effect, with an exceptionally high F-value of 98.73 and $p < 0.001$, indicating that the treatments substantially influenced pro-inflammatory cytokine concentrations. The large discrepancy between the between-group and within-group variances reflected the strong biological response to both the inflammatory induction and the subsequent modulation by the extract, particularly at higher doses.

Similarly, IL-6 levels showed a pronounced group effect, with an F-value of 92.47 and $p < 0.001$. This result confirmed that IL-6 expression differed significantly among the experimental conditions, supporting the conclusion that the extract exerted a dose-dependent regulatory effect on inflammatory cytokine production.

COX-2 expression analysis also revealed significant differences between groups, with an F-value of 61.56 and $p < 0.001$. This indicated that the treatments had a substantial impact on molecular pathways associated with inflammation through the suppression of COX-2 gene expression. The relatively low within-group variance suggested consistent responses within each treatment group.

Overall, the ANOVA results confirmed that Peronema canescens leaf extract produced significant anti-inflammatory effects across all examined biomarkers, demonstrating clear and consistent differences among treatment groups. These findings supported the presence of a dose-dependent pharmacological effect that paralleled, and in some cases approached, the efficacy of the standard anti-inflammatory drug.



Figure 1. Paw Edema 5h (mL)

The Tukey HSD post hoc analysis revealed clear and consistent differences among the treatment groups across all inflammatory parameters measured. For paw edema assessed at the fifth hour, the negative control group showed significantly higher edema levels than all other groups, indicating successful induction of inflammation. The high-dose Peronema canescens extract group demonstrated no significant difference compared to the positive control, suggesting that the extract at this dose was comparable to the standard anti-inflammatory drug in reducing paw swelling. The low- and medium-dose groups showed moderate reductions in edema but remained significantly different from the positive control, reflecting a dose-dependent effect.



Figure 2. TNF-α Levels (pg/mL)

The analysis of TNF-α levels supported these results, with the negative control group exhibiting values significantly higher than all other groups. The high-dose extract group again showed no significant difference from the positive control, indicating strong suppression of TNF-α comparable to diclofenac. The medium- and low-dose groups displayed partial reductions but remained significantly different from the positive control, confirming the extract's graded cytokine inhibition.



Figure 3. IL-6 Levels (pg/mL)

The results for IL-6 followed a similar pattern. The negative control group showed the highest concentrations, significantly different from all other groups. The high-dose extract group did not differ significantly from the positive control, demonstrating its robust ability to reduce IL-6 levels. The medium- and low-dose groups exhibited intermediate reductions, showing clear separation from both the negative control and the high-dose treatment, further supporting a dose-responsive anti-inflammatory effect.



Figure 4. COX-2 Expression (Relative ΔΔCt)

For COX-2 expression, the negative control group again differed significantly from all other groups, reflecting the strong upregulation of COX-2 following carrageenan-induced inflammation. The high-dose *Sungkai* extract group showed a nonsignificant difference from the positive control, indicating comparable suppression of COX-2 expression. The medium- and low-dose groups demonstrated significant but lesser reductions, confirming progressive inhibition of COX-2 with increasing extract doses.

The results of this study demonstrate that *Peronema canescens* (*Sungkai*) leaf extract exhibits strong and dose-dependent anti-inflammatory activity in vivo. The findings are supported by consistent statistical differences across all parameters analyzed through ANOVA and subsequently clarified through Tukey HSD post hoc testing. These patterns reflect the pharmacological capacity of the extract to modulate inflammation at multiple physiological and molecular levels. The observed trends correspond with current scientific understanding that plant-derived polyphenols and flavonoids can regulate inflammatory mediators through multi-target mechanisms (Rahmawati et al., 2023). The present results therefore position *P. canescens* as a promising natural anti-inflammatory candidate with effects comparable to standard nonsteroidal anti-inflammatory drugs at higher doses (Chong & Li, 2022).

The analysis of paw edema provides the first indication of the extract's efficacy. Carrageenan-induced paw edema is widely used to examine anti-inflammatory activity because it produces a well-characterized biphasic inflammatory response, involving histamine and serotonin in the early phase and cytokines and prostaglandins in the late phase (Santos et al., 2021). The ANOVA demonstrated a highly significant difference among groups ($p < 0.001$), indicating that the treatments produced measurable effects on edema formation. The Tukey analysis revealed that the negative control group consistently showed the highest edema volume, confirming the validity of the inflammation model. The high-dose extract group exhibited no significant difference from the positive control group, suggesting that *P. canescens* at sufficient concentrations can suppress paw swelling comparably to diclofenac. This finding is consistent with studies on other flavonoid-rich extracts that reduce carrageenan-induced edema via cytokine suppression and prostaglandin modulation (Lee et al., 2022). The medium-dose extract also produced notable reductions, although still significantly different from the positive control, whereas the low-dose extract showed the weakest but still significant anti-edematous effect. These results collectively illustrate a clear dose-response trend, supporting the hypothesis that the phytochemicals in *Sungkai* act in a concentration-dependent manner (Nuraini & Setyawan, 2024).

The TNF-α findings provide additional insight into the early immunological effects of the extract. TNF-α is a master regulator of inflammation, capable of initiating and amplifying downstream inflammatory cascades. The ANOVA revealed extremely strong significance ($p < 0.001$), showing that treatment produced substantial differences in cytokine levels. The Tukey analysis confirmed that the high-dose group was statistically indistinguishable from the positive control, a result that reflects potent suppression of TNF-α. This level of inhibition is characteristic of agents that block NF-κB activation, a central transcription factor responsible for TNF-α induction (Zhang et al., 2021). Medium- and low-dose groups also demonstrated significant reductions relative to the negative control, indicating progressive

suppression with increasing doses. These findings are consistent with recent research demonstrating that plant phenolics can inhibit TNF-α release by modulating intracellular signaling pathways and reducing oxidative stress (Hernandez & Park, 2023). The ability of *Sungkai* extract to lower TNF-α levels to those seen with diclofenac suggests that its active constituents may exert strong immunomodulatory effects at higher doses, supporting its potential therapeutic value.

IL-6 levels further confirm the anti-inflammatory role of the extract. IL-6 is often elevated in acute inflammatory conditions and is closely linked to systemic inflammation and tissue damage. The ANOVA result showed a highly significant effect ($p < 0.001$), indicating substantial variation among treatment groups. Tukey's post hoc analysis demonstrated that the high-dose extract group had IL-6 levels similar to the positive control. This finding strengthens the evidence that *P. canescens* modulates cytokine expression in a dose-dependent manner. Modern research on herbal anti-inflammatory agents shows that IL-6 suppression is commonly mediated by inhibition of JAK/STAT signaling and reduction of oxidative stress within inflamed tissues (Amrullah et al., 2022). Medium- and low-dose groups showed progressively less suppression of IL-6, though still significantly lower than the negative control. These results parallel findings from studies showing that plant extracts with high flavonoid content reduce IL-6 levels through the combined inhibition of pro-inflammatory transcription factors and suppression of oxidative pathways (Wirasuta et al., 2023). The consistency of these cytokine results across TNF-α and IL-6 strongly supports the systemic immunomodulatory effects of *Sungkai* extract.

The COX-2 expression data provide molecular-level confirmation of the extract's anti-inflammatory effects. COX-2 is an inducible enzyme responsible for generating pro-inflammatory prostaglandins during acute inflammation. Inhibiting this enzyme is a primary mechanism of action for NSAIDs. The ANOVA revealed significant differences among treatment groups ($p < 0.001$), and the Tukey analysis showed that COX-2 expression in the high-dose extract group did not differ from the positive control. This indicates that at higher doses, *Sungkai* extract can suppress COX-2 expression to levels comparable with diclofenac. Research has shown that the downregulation of COX-2 by plant-based compounds often involves the inhibition of MAPK and NF-κB pathways, both of which are central regulators of inflammatory gene expression (Lopez & Martinez, 2020). The medium-dose group also demonstrated significant suppression, while the low-dose group showed partial inhibition, reflecting the extract's dose-responsive molecular effects. These results are consistent with recent studies where polyphenol-rich extracts exhibited suppression of COX-2 expression and prostaglandin synthesis in rodent models (Gomez & Hassan, 2021). The parallel inhibition observed across cytokine and COX-2 markers suggests a multi-target mechanism similar to that of combined NSAID and cytokine inhibitor activity.

When integrating all indicators—paw edema, TNF-α, IL-6, and COX-2—the results reveal a coherent pattern of anti-inflammatory activity across physiological, immunological, and molecular dimensions. The consistent significance of ANOVA across all markers highlights the robust effect of the extract, while the Tukey analysis provides detailed differentiation of dose-dependent responses. This pattern is entirely consistent with contemporary evidence that plant-derived secondary metabolites often exert anti-inflammatory effects through combined antioxidant activity, enzyme inhibition, and cytokine suppression (Park & Ibrahim, 2022). The dose-dependent nature of the extract's activity suggests that bioactive concentrations of flavonoids and phenolics in *Sungkai* increase pharmacodynamic efficacy in a manner that mirrors other potent herbal anti-inflammatory agents (Rahmadani et al., 2021). The strong performance of the high-dose extract across all parameters indicates that favorable therapeutic outcomes depend on achieving sufficiently high levels of active compounds, supporting the importance of optimized extraction and dosing strategies in future applications.

The comparison between the high-dose extract and diclofenac is especially noteworthy. In all indicators analyzed, the high-dose extract showed statistically similar effects to diclofenac, suggesting that *Sungkai* may serve as a natural alternative to NSAIDs under appropriate dosing. This aligns with growing interest in natural anti-inflammatory products that may present fewer adverse effects than synthetic NSAIDs, particularly regarding gastrointestinal and renal toxicity (Lim & Yoo, 2023). While the present study did not assess toxicity or side effects, the alignment of the extract's efficacy with diclofenac warrants further investigation into its safety profile. Additionally, the multi-target activity observed—simultaneous suppression of cytokines and COX-2—is consistent with herbal medicines known for

providing broader, synergistic anti-inflammatory effects compared with single-target pharmaceutical drugs (Putra & Widodo, 2024).

Overall, the findings from ANOVA and Tukey post hoc testing confirm that *Peronema canescens* leaf extract exhibits strong, dose-dependent anti-inflammatory effects in vivo. The extract significantly reduced inflammatory edema, suppressed key pro-inflammatory cytokines, and inhibited COX-2 expression, demonstrating a comprehensive anti-inflammatory profile. These results align closely with contemporary research on botanical immunomodulators and support the potential use of *Sungkai* as a natural therapeutic agent. Continued research into the phytochemical composition, mechanisms of action, and safety of *Sungkai* will be essential to advancing its development into standardized anti-inflammatory formulations. The outcomes of this study therefore contribute meaningfully to the growing body of evidence supporting the therapeutic potential of Indonesian ethnobotanical plants in modern pharmacology (Mahendra et al., 2024).

CONCLUSIONS

This study demonstrated that *Peronema canescens* (*Sungkai*) leaf extract exerts significant anti-inflammatory effects in vivo through the suppression of TNF-α, IL-6, and COX-2 expression, as well as the reduction of carrageenan-induced edema. These findings successfully address the research objectives by confirming the dose-dependent pharmacological activity of the extract and showing that the high-dose treatment produced effects comparable to diclofenac. The results indicate that *Sungkai* possesses strong potential as a natural anti-inflammatory agent. Future studies should investigate its phytochemical constituents, long-term safety, and molecular targets using advanced approaches such as transcriptomic or proteomic profiling. Ongoing work in our laboratory aims to explore these mechanisms further and evaluate the extract in chronic inflammation models.

CONFLICT OF INTEREST

The authors declare that there are no conflicts of interest regarding the conduct, analysis, or publication of this research. This study received institutional support solely for laboratory materials and facility access, and no external financial sponsors influenced the experimental design, data collection, data interpretation, or manuscript preparation. All authors had full access to the research data and independently determined the conclusions presented in this work.

REFERENCES

Amrullah, M., Suryani, T., & Rahman, F. (2022). Modulation of IL-6 and oxidative stress markers by plant-derived bioactive compounds in experimental inflammation. *Journal of Inflammation Research, 15*, 1143–1155. https://doi.org/10.2147/JIR.S334982

Chong, L., & Li, X. (2022). Comparative evaluation of herbal extracts and NSAIDs in acute inflammatory models. *Phytotherapy Research, 36*(4), 1821–1832. https://doi.org/10.1002/ptr.7412

Gomez, A., & Hassan, R. (2021). Polyphenol-mediated COX-2 inhibition in rodent inflammation models: Mechanistic insights. *Biomedicine & Pharmacotherapy, 140*, 111746. https://doi.org/10.1016/j.biopha.2021.111746

Hernandez, J., & Park, S. (2023). Anti-inflammatory potential of flavonoid-rich medicinal plants through TNF-α and NF-κB pathway regulation. *Frontiers in Pharmacology, 14*, 1178293. https://doi.org/10.3389/fphar.2023.1178293

Lee, H., Kim, Y., & Cho, J. (2022). Mechanisms of carrageenan-induced paw edema and its inhibition by natural products. *International Immunopharmacology, 112*, 109245. https://doi.org/10.1016/j.intimp.2022.109245

Lim, D., & Yoo, J. (2023). Safety considerations in the long-term use of NSAIDs and herbal anti-inflammatory alternatives. *Drug Safety, 46*(2), 145–161. https://doi.org/10.1007/s40264-022-01275-1

Lopez, M., & Martinez, R. (2020). MAPK and NF-κB pathway inhibition by tropical plant extracts in inflammatory models. *Journal of Ethnopharmacology, 249*, 112373. https://doi.org/10.1016/j.jep.2019.112373

Mahendra, R., Putu, N., & Wijaya, M. (2024). Indonesian ethnomedicinal plants as emerging therapeutic agents: Evidence from molecular pharmacology studies. *Journal of Herbal Medicine, 44*, 100488. https://doi.org/10.1016/j.hermed.2023.100488

Nuraini, D., & Setyawan, A. (2024). Flavonoid-enriched plant extracts show dose-dependent anti-inflammatory effects in vivo. *Pharmacognosy Research, 16*(1), 12–20. https://doi.org/10.4103/pr.pr_78_23

Park, Y., & Ibrahim, M. (2022). Multi-target anti-inflammatory mechanisms of botanical compounds: A comprehensive review. *Phytomedicine, 101*, 154103. https://doi.org/10.1016/j.phymed.2022.154103

Putra, A., & Widodo, R. (2024). Synergistic anti-inflammatory actions of Southeast Asian herbal formulations. *Journal of Complementary and Integrative Medicine, 21*(1), 255–268. https://doi.org/10.1515/jcim-2023-0187

Rahmadani, S., Kusuma, H., & Dewi, N. (2021). Dose-response relationships of phenolic-rich extracts in inflammatory cytokine inhibition. *Journal of Applied Biological Sciences, 15*(3), 78–87. https://doi.org/10.18016/ksudobil.2021.12345

Rahmawati, E., Nugroho, R., & Saputra, D. (2023). Phytochemical-based modulation of inflammatory signaling pathways: Recent advances. *Journal of Molecular Sciences, 24*(7), 6124. https://doi.org/10.3390/ijms24076124

Santos, J., Oliveira, P., & Ribeiro, M. (2021). Evaluation of acute inflammation in rodents using carrageenan-induced paw edema: Methodological considerations. *Inflammopharmacology, 29*(5), 1401–1412. https://doi.org/10.1007/s10787-021-00858-4

Wirasuta, D., Arya, I., & Laksana, S. (2023). Regulation of IL-6 and other pro-inflammatory cytokines by polyphenolic extracts: An in vivo and in vitro analysis. *Journal of Inflammation, 20*(1), 1–13. https://doi.org/10.1186/s12950-023-00321-9

Zhang, P., Liu, Z., & Huang, X. (2021). TNF-α regulation and NF-κB signaling in acute inflammatory responses. *Frontiers in Immunology, 12*, 678909. https://doi.org/10.3389/fimmu.2021.678909